We found that treatment of rd10 mice with sPIF, an IDE activator, ameliorated vision loss and preserved photoreceptor number and structure, suggesting that IDE may constitute a novel therapeutic target for RP. This evidence concerns the gene MROH2B and retinitis pigmentosa 1.